Medical Oncology

Daniel James George, MD

Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-4615
Email address daniel.george@duke.edu

Education and Training

  • Fellow in Medical Oncology, Medicine, Johns Hopkins University, 1995 - 1998
  • Medical Resident, Medicine, Johns Hopkins University, 1992 - 1995
  • M.D., Duke University, 1992

Grants

Publications

Humeniuk, MS, Gupta, RT, Healy, P, McNamara, M, Ramalingam, S, Harrison, M, George, D, Zhang, T, Wu, Y, and Armstrong, AJ. "Platinum sensitivity in metastatic prostate cancer: does histology matter?." Prostate cancer and prostatic diseases 21, no. 1 (April 2018): 92-99.

PMID
29230006
Full Text

Choueiri, TK, Hessel, C, Halabi, S, Sanford, B, Michaelson, MD, Hahn, O, Walsh, M, Olencki, T, Picus, J, Small, EJ, Dakhil, S, Feldman, DR, Mangeshkar, M, Scheffold, C, George, D, and Morris, MJ. "Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update." European journal of cancer (Oxford, England : 1990) 94 (March 15, 2018): 115-125.

PMID
29550566
Full Text

Clarke, JM, George, DJ, Lisi, S, and Salama, AKS. "Immune Checkpoint Blockade: The New Frontier in Cancer Treatment." Targeted oncology 13, no. 1 (February 13, 2018): 1-20.

PMID
29441437
Full Text

Ramalingam, S, George, DJ, and Harrison, MR. "How we treat brain metastases in metastatic renal cell carcinoma." Clinical advances in hematology & oncology : H&O 16, no. 2 (February 2018): 110-114.

PMID
29741510
Scholars@Duke

Koshkin, VS, Barata, PC, Zhang, T, George, DJ, Atkins, MB, Kelly, WJ, Vogelzang, NJ, Pal, SK, Hsu, J, Appleman, LJ, Ornstein, MC, Gilligan, T, Grivas, P, Garcia, JA, and Rini, BI. "Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma." Journal for immunotherapy of cancer 6, no. 1 (January 29, 2018): 9-.

PMID
29378660
Full Text

George, DJ, Martini, J-F, Staehler, M, Motzer, RJ, Magheli, A, Escudier, B, Gerletti, P, Li, S, Casy, M, Laguerre, B, Pandha, H, Pantuck, A, Patel, A, Lechuga, MJ, and Ravaud, A. "Immune biomarkers predictive for disease-free survival with adjuvant sunitinib in high-risk locoregional renal cell carcinoma: from randomized phase III S-TRAC study." Clinical cancer research : an official journal of the American Association for Cancer Research (January 26, 2018).

PMID
29374054
Full Text

Zhu, J, Armstrong, AJ, Friedlander, TW, Kim, W, Pal, SK, George, DJ, and Zhang, T. "Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond." Journal for immunotherapy of cancer 6, no. 1 (January 25, 2018): 4-. (Review)

PMID
29368638
Full Text

Motzer, RJ, Ravaud, A, Patard, J-J, Pandha, HS, George, DJ, Patel, A, Chang, Y-H, Escudier, B, Donskov, F, Magheli, A, Carteni, G, Laguerre, B, Tomczak, P, Breza, J, Gerletti, P, Lechuga, M, Lin, X, Casey, M, Serfass, L, Pantuck, AJ, and Staehler, M. "Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results." European urology 73, no. 1 (January 2018): 62-68.

PMID
28967554
Full Text

Armstrong, AJ, Antonarakis, ES, Taplin, M-E, Kelly, WK, Beltran, H, Fizazi, K, Dahut, WL, Shore, N, Slovin, S, George, D, Carducci, MA, Corn, P, Danila, D, Dreicer, R, Heath, E, Rathkopf, D, Liu, G, Nanus, D, Stein, M, Smith, MR, Sternberg, C, Wilding, G, Nelson, PS, Halabi, S, Kantoff, P, Clarke, NW, Evans, CP, Heidenreich, A, Mottet, N, Gleave, M, Morris, MJ, and Scher, HI. "Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet." Annals of oncology : official journal of the European Society for Medical Oncology 29, no. 1 (January 2018): 23-25.

PMID
29088323
Full Text

Zhu, J, Tucker, M, Wang, E, Grossman, JS, Armstrong, AJ, George, DJ, and Zhang, T. "Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer." Clinical genitourinary cancer 15, no. 6 (December 2017): e1137-e1141.

PMID
28780018
Full Text

Pages